News AB Science

Stocks

AB

FR0010557264

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-17 EDT			5-day change	1st Jan Change
0.8800 ^EUR	+2.09%		-3.30%	-42.71%

06-10	AB Science presents new data on Masitinib
05-17	AB Science S.A. announced that it has received $2.989368 million in funding	CI

All News

Mentions Relevance

06-17	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042	GL
06-10	AB Science presents new data on Masitinib
06-09	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL
06-02	AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share	GL
05-26	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of EUR4.00 per share	AQ
05-25	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share	GL
05-17	AB Science S.A. announced that it has received $2.989368 million in funding	CI
05-13	AB Science : Annual financial results as of 31 December, 2025	PU
05-13	AB Science reports its revenues for the year 2025 and provides an update on its activities	GL
05-13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-03	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
04-29	AB Science announces successful capital increase
04-29	AB Science announces the successful completion of a EUR 3.2 million private placement	GL
04-28	AB Science Reaches Maturity Extension Deal with Lenders	MT
04-27	AB Science announces major agreement with creditors
04-27	AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors	GL
04-27	AB Science SA Announces Final Agreement on Renegotiation of Repayment Terms of Loans With Financial Creditors	CI
04-21	Positive data for AB Science's masitinib published on medRxiv
04-20	AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients	GL
04-20	AB Science Announces New Publication Demonstrating Substantial Survival Benefits and Preserved Quality of Life with Masitinib in Amyotrophic Lateral Sclerosis Patients	CI
04-16	AB Science temporarily halts Europe clinical trials ahead of strategic reorganization	RE
04-16	AB Science provides an update on its clinical development program.	GL
04-16	AB Science Provides Update on Clinical Development Program	CI
02-24	AB Science : annonce l’identification d’un biomarqueur plasmatique marqueur de l’activité du masitinib dans le traitement de la SLA	PU
02-24	AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS	GL